Contineum Therapeutics Files 8-K

TL;DR

Contineum Therapeutics filed an 8-K on Dec 11, 2025, reporting a material agreement and other events.

AI Summary

Contineum Therapeutics, Inc. filed an 8-K on December 15, 2025, reporting on events that occurred on December 11, 2025. The filing indicates a material definitive agreement was entered into, along with other events and financial statements/exhibits. The company, formerly known as Pipeline Therapeutics, Inc., is based in San Diego, California.

Why It Matters

This 8-K filing signals significant corporate activity for Contineum Therapeutics, potentially involving new agreements or strategic shifts that could impact its business operations and future prospects.

Risk Assessment

Risk Level: medium — An 8-K filing can indicate significant corporate events, but without details on the specific agreements or events, the immediate risk level is moderate.

Key Numbers

• 001-42001 — SEC File Number (Identifies the company's filing history with the SEC.)
• 27-1467257 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Contineum Therapeutics, Inc. (company) — Registrant
• Pipeline Therapeutics, Inc. (company) — Former company name
• December 11, 2025 (date) — Date of earliest event reported
• December 15, 2025 (date) — Filing date
• San Diego, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — tered Class A Common Stock , par value $0.001 per share CTNM The Nasdaq Global Mar
• $12.25 — price to the public in the Offering was $12.25 per Share. The Underwriters purchased t
• $11.515 — he Underwriting Agreement at a price of $11.515 per Share. Under the terms of the Under
• $84.2 m — ering are estimated to be approximately $84.2 million, after deducting underwriting dis
• $75.0 million — ease to announce a proposed offering of $75.0 million of shares of its Class A common stock p
• $90.0 million — announce that it had priced an upsized $90.0 million offering of shares of its Class A commo
• $75.0 Million — ntineum Therapeutics Announces Proposed $75.0 Million Public Offering." 99.2 Press release
• $90.0 Million — erapeutics Announces Pricing of Upsized $90.0 Million Public Offering." 104 Cover Page Int

Filing Documents

• ctnm20251214_8k.htm (8-K) — 41KB
• ex_898779.htm (EX-1.1) — 232KB
• ex_898780.htm (EX-5.1) — 9KB
• ex_898781.htm (EX-99.1) — 10KB
• ex_898782.htm (EX-99.2) — 10KB
• banner2.jpg (GRAPHIC) — 3KB
• banner_bottom.jpg (GRAPHIC) — 10KB
• gdbanner.jpg (GRAPHIC) — 7KB
• logo.jpg (GRAPHIC) — 3KB
• logo_gd.jpg (GRAPHIC) — 5KB
• 0001437749-25-037842.txt ( ) — 542KB
• ctnm-20251211.xsd (EX-101.SCH) — 3KB
• ctnm-20251211_def.xml (EX-101.DEF) — 12KB
• ctnm-20251211_lab.xml (EX-101.LAB) — 15KB
• ctnm-20251211_pre.xml (EX-101.PRE) — 12KB
• ctnm20251214_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On December 11, 2025, Contineum Therapeutics, Inc., a Delaware corporation (the "Company"), entered into an Underwriting Agreement (the "Underwriting Agreement") with Goldman Sachs & Co. LLC and Leerink Partners LLC, acting as representatives of the several underwriters named in the Underwriting Agreement (the "Underwriters"), relating to the sale of 7,346,938 shares (the "Shares") of the Company's Class A common stock, par value $0.001 per share (the "Offering"). The price to the public in the Offering was $12.25 per Share. The Underwriters purchased the Shares from the Company pursuant to the Underwriting Agreement at a price of $11.515 per Share. Under the terms of the Underwriting Agreement, the Company has granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 1,102,040 shares of its Class A common stock. The net proceeds to the Company from the Offering are estimated to be approximately $84.2 million, after deducting underwriting discounts and commissions and estimated Offering expenses payable by the Company, assuming no exercise by the Underwriters of their option to purchase additional shares of Class A common stock. The Offering closed on December 15, 2025. The Offering was made pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-287275), filed with the Securities and Exchange Commission ("SEC") on May 14, 2025, which was declared effective by the SEC on May 23, 2025, and the prospectus included therein (the "Registration Statement"), a preliminary prospectus supplement, dated December 11, 2025, filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the "Securities Act"), and a final prospectus supplement, dated December 11, 2025, filed with the SEC pursuant to Rule 424(b) under the Securities Act. The Underwriting Agreement contains customary representations, warranties and agreements by the Company

01 Other Events

Item 8.01 Other Events. On December 11, 2025, the Company issued a press release to announce a proposed offering of $75.0 million of shares of its Class A common stock pursuant to the Registration Statement (the "Offering Press Release"). A copy of the Offering Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. On December 11, 2025, the Company also issued a press release to announce that it had priced an upsized $90.0 million offering of shares of its Class A common stock (the "Pricing Press Release"). A copy of the Pricing Press Release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated December 11, 2025, by and among the Company, Goldman Sachs & Co. LLC and Leerink Partners LLC. 5.1 Opinion and Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP. 23.1 Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (included in Exhibit 5.1). 99.1 Press release issued by the Company, dated December 11, 2025, titled "Contineum Therapeutics Announces Proposed $75.0 Million Public Offering." 99.2 Press release issued by the Company, dated December 11, 2025, titled "Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 15, 2025 Contineum Therapeutics, Inc. By: /s/ Peter Slover Peter Slover Chief Financial Officer Principal Financial Officer and Principal Accounting Officer

View Full Filing

View this 8-K filing on SEC EDGAR